<code id='DBC9469198'></code><style id='DBC9469198'></style>
    • <acronym id='DBC9469198'></acronym>
      <center id='DBC9469198'><center id='DBC9469198'><tfoot id='DBC9469198'></tfoot></center><abbr id='DBC9469198'><dir id='DBC9469198'><tfoot id='DBC9469198'></tfoot><noframes id='DBC9469198'>

    • <optgroup id='DBC9469198'><strike id='DBC9469198'><sup id='DBC9469198'></sup></strike><code id='DBC9469198'></code></optgroup>
        1. <b id='DBC9469198'><label id='DBC9469198'><select id='DBC9469198'><dt id='DBC9469198'><span id='DBC9469198'></span></dt></select></label></b><u id='DBC9469198'></u>
          <i id='DBC9469198'><strike id='DBC9469198'><tt id='DBC9469198'><pre id='DBC9469198'></pre></tt></strike></i>

          
          WSS

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion